Adial Pharmaceuticals Inc (ADIL)
0.9711
0.00 (0.00%)
USD |
NASDAQ |
Oct 04, 16:00
0.96
-0.01
(-1.14%)
After-Hours: 20:00
Adial Pharmaceuticals SG&A Expense (Annual): 5.621M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 5.621M |
| December 31, 2022 | 8.909M |
| December 31, 2021 | 9.345M |
| December 31, 2020 | 5.075M |
| December 31, 2019 | 4.279M |
| Date | Value |
|---|---|
| December 31, 2018 | 6.619M |
| December 31, 2017 | 0.8132M |
| December 31, 2016 | 0.2647M |
| December 31, 2015 | 0.4971M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
4.279M
Minimum
2019
9.345M
Maximum
2021
6.646M
Average
5.621M
Median
2023
SG&A Expense (Annual) Benchmarks
| SeaStar Medical Holding Corp | 8.237M |
| NovaBay Pharmaceuticals Inc | 12.83M |
| Palatin Technologies Inc | 12.27M |
| iBio Inc | 11.67M |
| Theriva Biologics Inc | 7.12M |